FIGURE 8.

ASN12 reduces intraneuronal Aβ and ameliorates Aβ-induced neuropathology in the Line41 APPtg mouse. Line41 APPtg and non-tg mice received ASN12, SN5 (1 mg/kg), or saline intraperitoneally twice weekly for 3 weeks. Following protein delivery, mice were sacrificed, brains removed, divided sagitally with one-half fixed in paraformaldehyde. A, representative brain sections were stained for Aβ (4G8, 82E1, or D129), neuronal dendritic marker (MAP2), post-synaptic marker (synaptophysin), or astrocytic marker (GFAP). B, image analysis of the % area of the neuropil covered or corrected optical density for images analyzed. * indicates statistical significance p < 0.05 when compared with non-tg controls. # indicates statistical significance p < 0.05 when ASN12 or SN5 are compared with saline-treated APPtg mice. Scale bars = 7 μm. n = 5 for each group.